×

India

Zydus Cadila Vaccine For Kids Above 12 Likely To Be Available By July-End: NTAGI Chairman

As per Dr. Arora, the trial was almost complete and the government might be able to start administering this vaccine to children of 12-18 age group by the end of July.

Zydus cadilla
Zydus Cadila vaccine -(Image Courtesy: Zydus Cadila)

New Delhi: The Chairman of the COVID-19 working group of the National Technical Advisory Group of Immunisation (NTAGI), Dr. NK Arora, on Sunday (June 27) informed that the Zydus Cadila vaccine for children is likely to be available by July end or in August.

As per Dr. Arora, the trial was almost complete and the government might be able to start administering this vaccine to children of 12-18 age group by the end of July.

ALSO READ: Covid-19 Vaccine Update: India Vaccinates 32.1 Crore People, Vaccine For 12-18 Age Group Soon

“Trial for Zydus Cadila vaccine is almost complete. By July end or in August, we might be able to start administering this vaccine to children of 12-18 age group,” Dr Arora said.

Dr. Arora also said that the ICMR has come up with a study which says third wave is likely to come late.

“We have window period of 6-8 months to immunise everybody in country. In coming days, our target is to administer 1 crore doses every day,” he said.

Earlier the Centre on Saturday informed the Supreme Court of India that Zydus Cadila, Developed by DNA vaccines, has finished its clinical trial for the age group of 12 to 18 years.

Subject to the statutory permissions, the Covid-19 vaccine may be made available in near future for kids.

ALSO READ: COVID-19 Vaccine For Kids Will Be Key in Reopening Schools, Outdoor Activities: Randeep Guleria

The central government also added that on May 12, 2021, the Drugs Controller General of India (DCGI) granted the permission to Bharat Biotech to carryout clinical trials on healthy volunteers between two years to 18 years for their covid vaccine Covaxin.

Meanwhile AIIMS Director Randeep Guleria on Sunday said that it will be a milestone for India if it is able to provide its children with COVID-19 vaccines which will help in reporting schools and allow them to mingle in outdoor activities.

Guleria said that the Phase 2 and Phase 3 trial results of Bharat Biotech’s Covaxin were expected by September following which the data could be sent to the Drug Controller General of India (DCGI) for approval.